All In Biotech

Drug Trial Radar · NCT06023186

Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM

Coronary Flow Reserve in oHCM Patients Before and After 12 Months of Standard-of-care Mavacamten Treatment as Assessed by PET/CT

Last checked: Nov 20, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Nov 3, 2023

Primary completion

Aug 31, 2026

Study completion Sep 30, 2026

Sponsor

Lead sponsor
Michael AyersAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bristol-Myers Squibb
First posted
Sep 5, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this observational study is to measure the effect of mavacamten treatment on blood flow in the heart muscle (myocardium) in patients with obstructive hypertrophic cardiomyopathy. The main question it aims to answer is: • Does mavacamten treatment improve blood flow in the heart muscle? Participants will take mavacamten at the direction of their treating physician. Participants will complete 2 myocardial Positron Emission Tomography and Computed Tomography (PET-CT) scans. The first scan will be completed before participants start taking mavacamten. The scan will be repeated after 12 months of mavacamten treatment.

Conditions

  • Obstructive Hypertrophic Cardiomyopathy

Interventions

  • mavacamtenDrug

    Study participants will receive mavacamten under the standard of care

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in myocardial perfusion reserve after 12 months of mavacamten treatment.Time frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Virginia

    Charlottesville, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.